Company intelligence / Profile preview
Neovii Pharmaceuticals
Rapperswil, Switzerland
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Neovii is a global biopharmaceutical company focused on transplantation medicine, hematology, and immune disorders. Their lead commercial product, Grafalon (rabbit anti-human T-lymphocyte immunoglobulin), is widely used for the prevention and treatment of graft-versus-host disease (GvHD) and the prevention of rejection in solid organ transplantation.
- Therapeutic areas
- HematologyNephrologyImmunologyCardiovascularGastroenterology
- Modalities
- Polyclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Fresenius SE & Co. KGaA
Beyond the preview
Go deeper on Neovii Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neovii Pharmaceuticals.